(Q37976121)

26 August 2017

Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development? (English)

1 reference

26 August 2017

1 reference

1 reference

1 reference

1 reference

Rong Deng

1

1 reference

26 August 2017

Feng Jin

series ordinal

2

1 reference

26 August 2017

Saileta Prabhu

series ordinal

3

1 reference

26 August 2017

Suhasini Iyer

series ordinal

4

1 reference

26 August 2017

language of work or name

English

0 references

publication date

17 January 2012

1 reference

Expert Opinion on Drug Metabolism & Toxicology

26 August 2017

1 reference

26 August 2017

8

1 reference

26 August 2017

2

1 reference

26 August 2017

141-160

1 reference

Antibody pharmacokinetics and pharmacodynamics

26 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Clinical pharmacokinetics of therapeutic monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Passage of intravenous immunoglobulin and interaction with the CNS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Tissue distribution and receptor-mediated clearance of anti-CD11a antibody in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Metabolic properties of IgG subclasses in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Engineered human IgG antibodies with longer serum half-lives in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

An engineered human IgG1 antibody with longer serum half-life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

FcRn: the neonatal Fc receptor comes of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Population pharmacokinetics of therapeutic monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Elimination mechanisms of therapeutic monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Population pharmacokinetics of infliximab in patients with ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Improved biodistribution, tumor targeting, and reduced immunogenicity in mice with a gamma 4 variant of Campath-1H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Complex pharmacokinetics of a humanized antibody against human amyloid beta peptide, anti-abeta Ab2, in nonclinical species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Effects of charge on antibody tissue distribution and pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Reduced elimination of IgG antibodies by engineering the variable region.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

The fate and function of therapeutic antiaddiction monoclonal antibodies across the reproductive cycle of rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Oncogenic mutations as predictive factors in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

From the bench to the bedside: ways to improve rituximab efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Pharmacologic target-mediated drug disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

General pharmacokinetic model for drugs exhibiting target-mediated drug disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Target-mediated drug disposition model for drugs that bind to more than one target.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Effect of Target Dynamics on Pharmacokinetics of a Novel Therapeutic Antibody against the Epidermal Growth Factor Receptor: Implications for the Mechanisms of Action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Therapeutic monoclonal antibody concentration monitoring: free or total?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Bioanalytical approaches to quantify "total" and "free" therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Critical comparison of MS and immunoassays for the bioanalysis of therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Interspecies scaling of therapeutic monoclonal antibodies: initial look

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Scaling pharmacodynamics from in vitro and preclinical animal studies to humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Integrated pharmacokinetic-pharmacodynamic modeling and allometric scaling for optimizing the dosage regimen of the monoclonal ior EGF/r3 antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Estimating the starting dose for entry into humans: principles and practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

In vitro potency, pharmacokinetic profiles, and pharmacological activity of optimized anti-IL-21R antibodies in a mouse model of lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Simultaneous Modeling of Abciximab Plasma Concentrations and ex Vivo Pharmacodynamics in Patients Undergoing Coronary Angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

A Theoretical Model of γ-Globulin Catabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.643868

10.1517/17425255.2012.643868

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference